ArticleFolia microbiologica2026
Mesoporous and magnetic nanoparticle-based delivery of 1-hydroxyphenazine extracted from Pseudomonas aeruginosa enhances antimicrobial activity against different bacterial pathogens.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) remains one of the most critical global health challenges, demanding innovative therapeutics beyond conventional antibiotics. In this study, Pseudomonas aeruginosa strain KAEH25, isolated from rhizospheric soil in Menoufia, Egypt, was identified as a potent producer of 1-hydroxyphenazine (1-HPZ), a redox-active phenazine derivative exhibiting broad-spectrum antimicrobial activity. The compound was extracted, purified, and characterized by ultraviolet–visible (UV–Vis) spectrophotometry, Fourier-transform infrared spectroscopy (FTIR), high-performance liquid chromatography (HPLC), nuclear magnetic resonance spectroscopy (NMR), and gas chromatography–mass spectrometry (GC–MS), confirming its molecular identity and purity. To overcome its poor solubility and instability, 1-HPZ was encapsulated into mesoporous silica and magnetic Fe₃O₄ nanoparticles. Nanomaterials were synthesized and characterized using dynamic light scattering (DLS), zeta potential, and transmission electron microscopy (TEM), confirming nanoscale uniformity, high surface area, and successful drug loading. Molecular docking studies (Schrödinger 2023-4) revealed strong binding affinities of 1-HPZ toward key bacterial enzymes including topoisomerase IV (–7.909 kcal/mol), DNA gyrase (–6.650 kcal/mol), and RNA polymerase (–6.750 kcal/mol), implying multitarget inhibition of DNA replication, cell wall biosynthesis, and protein synthesis. Molecular dynamics simulations (Materials Studio 2024, COMPASS III) demonstrated favorable insertion energies (≈–4.8 × 10⁶ kcal/mol) for both free and nanoformulated 1-HPZ into 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) lipid bilayers, indicating strong membrane affinity and potential for enhanced cellular uptake. Experimentally, the 1-HPZ-loaded mesoporous nanoparticles showed the most potent antibacterial effect, producing inhibition zones up to 25 mm against Listeria monocytogenes and Escherichia coli, surpassing free 1-HPZ. Time-kill and minimum inhibitory concentration/minimum bactericidal concentration (MIC/MBC) assays confirmed bactericidal activity at low concentrations (MIC 4–16 µg/mL; MBC 8–32 µg/mL), outperforming both magnetic formulations and free 1-HPZ. These findings validate that mesoporous nanocarriers significantly enhance the solubility, stability, and antibacterial potency of 1-HPZ while maintaining biocompatibility. This integrated experimental and computational investigation demonstrates that coupling a microbial natural product with nanotechnology offers a promising route to overcome multidrug resistance. The 1-HPZ–mesoporous system provides a robust platform for next-generation antimicrobial therapies and magnetically guided drug delivery applications.
Indexed as
Identifiers
42008076What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.